The estimated Net Worth of Mark J Gergen is at least $705 mil dollars as of 15 January 2016. Mr Gergen owns over 15,000 units of Poseida Therapeutics stock worth over $45,669 and over the last 11 years he sold PSTX stock worth over $0. In addition, he makes $659,535 as CEO & Director at Poseida Therapeutics.
Mr has made over 2 trades of the Poseida Therapeutics stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of PSTX stock worth $127,500 on 15 January 2016.
The largest trade he's ever made was exercising 15,000 units of Poseida Therapeutics stock on 15 January 2016 worth over $127,500. On average, Mr trades about 1,765 units every 0 days since 2013. As of 15 January 2016 he still owns at least 15,748 units of Poseida Therapeutics stock.
You can see the complete history of Mr Gergen stock trades at the bottom of the page.
Mark J. Gergen J.D. is the CEO & Director at Poseida Therapeutics.
As the CEO & Director of Poseida Therapeutics, the total compensation of Mr D at Poseida Therapeutics is $659,535. There are 2 executives at Poseida Therapeutics getting paid more, with Dr. Eric M. Ostertag having the highest compensation of $858,677.
Mr D is 58, he's been the CEO & Director of Poseida Therapeutics since . There are 3 older and 5 younger executives at Poseida Therapeutics. The oldest executive at Poseida Therapeutics, Inc. is Harry J. Leonhardt Esq., J.D., 64, who is the Gen. Counsel, Chief Compliance Officer & Corp. Sec..
Mark's mailing address filed with the SEC is C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTER DRIVE SUITE 200, SAN DIEGO, CA, 92121.
Over the last 4 years, insiders at Poseida Therapeutics have traded over $7,666,974 worth of Poseida Therapeutics stock and bought 3,065,405 units worth $15,916,632 . The most active insiders traders include David Hirsch, Life Sciences Holdings Ltd ... y Eric Ostertag. On average, Poseida Therapeutics executives and independent directors trade stock every 18 days with the average trade being worth of $303,665. The most recent stock trade was executed by Eric Ostertag on 8 August 2022, trading 142,857 units of PSTX stock currently worth $500,000.
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
Poseida Therapeutics executives and other stock owners filed with the SEC include: